Decellularized lymph node scaffolding as a carrier for dendritic cells to induce anti-tumor immunity

Hung Jun Lin, Weu Wang, Yi You Huang, Wei Tsen Liao, Ting Yu Lin, Shyr Yi Lin, Der Zen Liu

Research output: Contribution to journalArticle

Abstract

In recent decades, the decellularized extracellular matrix (ECM) has shown potential as a promising scaffold for tissue regeneration. In this study, an organic acid decellularized lymph node (dLN) was developed as a carrier for dendritic cells (DCs) to induce antitumor immunity. The dLNs were prepared by formic acid, acetic acid, or citric acid treatment. The results showed highly efficient removal of cell debris from the lymph node and great preservation of ECM architecture and biomolecules. In addition, bone marrow dendritic cells (BMDCs) grown preferably inside the dLN displayed the maturation markers CD80, CD86, and major histocompatibility complex (MHC)-II, and they produced high levels of interleukin (IL)-1β, IL-6, and IL-12 cytokines when stimulated with ovalbumin (OVA) and CpG oligodeoxynucleotides (CPG-ODN). In an animal model, the BMDC-dLN completely rejected the E.G7-OVA tumor. Furthermore, the splenocytes from BMDC-dLN-immunized mice produced more interferon gamma, IL-4, IL-6, and IL-2, and they had a higher proliferation rate than other groups when re-stimulated with OVA. Hence, BMDC-dLN could be a promising DC-based scaffold for in vivo delivery to induce potent antitumor immunity.

Original languageEnglish
Article number553
JournalPharmaceutics
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 2019

Fingerprint

Dendritic Cells
Immunity
Lymph Nodes
Bone Marrow Cells
Ovalbumin
Neoplasms
formic acid
Extracellular Matrix
Interleukin-6
Tissue Scaffolds
Oligodeoxyribonucleotides
Interleukin-12
Major Histocompatibility Complex
Interleukin-1
Citric Acid
Acetic Acid
Interleukin-4
Interferon-gamma
Interleukin-2
Regeneration

Keywords

  • Cancer immunotherapy
  • Cell-based therapy
  • Decellularized scaffold
  • Dendritic cell
  • Lymph node

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Decellularized lymph node scaffolding as a carrier for dendritic cells to induce anti-tumor immunity. / Lin, Hung Jun; Wang, Weu; Huang, Yi You; Liao, Wei Tsen; Lin, Ting Yu; Lin, Shyr Yi; Liu, Der Zen.

In: Pharmaceutics, Vol. 11, No. 11, 553, 11.2019.

Research output: Contribution to journalArticle

@article{ec5083f6311743c4902531e94cefcba0,
title = "Decellularized lymph node scaffolding as a carrier for dendritic cells to induce anti-tumor immunity",
abstract = "In recent decades, the decellularized extracellular matrix (ECM) has shown potential as a promising scaffold for tissue regeneration. In this study, an organic acid decellularized lymph node (dLN) was developed as a carrier for dendritic cells (DCs) to induce antitumor immunity. The dLNs were prepared by formic acid, acetic acid, or citric acid treatment. The results showed highly efficient removal of cell debris from the lymph node and great preservation of ECM architecture and biomolecules. In addition, bone marrow dendritic cells (BMDCs) grown preferably inside the dLN displayed the maturation markers CD80, CD86, and major histocompatibility complex (MHC)-II, and they produced high levels of interleukin (IL)-1β, IL-6, and IL-12 cytokines when stimulated with ovalbumin (OVA) and CpG oligodeoxynucleotides (CPG-ODN). In an animal model, the BMDC-dLN completely rejected the E.G7-OVA tumor. Furthermore, the splenocytes from BMDC-dLN-immunized mice produced more interferon gamma, IL-4, IL-6, and IL-2, and they had a higher proliferation rate than other groups when re-stimulated with OVA. Hence, BMDC-dLN could be a promising DC-based scaffold for in vivo delivery to induce potent antitumor immunity.",
keywords = "Cancer immunotherapy, Cell-based therapy, Decellularized scaffold, Dendritic cell, Lymph node",
author = "Lin, {Hung Jun} and Weu Wang and Huang, {Yi You} and Liao, {Wei Tsen} and Lin, {Ting Yu} and Lin, {Shyr Yi} and Liu, {Der Zen}",
year = "2019",
month = "11",
doi = "10.3390/pharmaceutics11110553",
language = "English",
volume = "11",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Decellularized lymph node scaffolding as a carrier for dendritic cells to induce anti-tumor immunity

AU - Lin, Hung Jun

AU - Wang, Weu

AU - Huang, Yi You

AU - Liao, Wei Tsen

AU - Lin, Ting Yu

AU - Lin, Shyr Yi

AU - Liu, Der Zen

PY - 2019/11

Y1 - 2019/11

N2 - In recent decades, the decellularized extracellular matrix (ECM) has shown potential as a promising scaffold for tissue regeneration. In this study, an organic acid decellularized lymph node (dLN) was developed as a carrier for dendritic cells (DCs) to induce antitumor immunity. The dLNs were prepared by formic acid, acetic acid, or citric acid treatment. The results showed highly efficient removal of cell debris from the lymph node and great preservation of ECM architecture and biomolecules. In addition, bone marrow dendritic cells (BMDCs) grown preferably inside the dLN displayed the maturation markers CD80, CD86, and major histocompatibility complex (MHC)-II, and they produced high levels of interleukin (IL)-1β, IL-6, and IL-12 cytokines when stimulated with ovalbumin (OVA) and CpG oligodeoxynucleotides (CPG-ODN). In an animal model, the BMDC-dLN completely rejected the E.G7-OVA tumor. Furthermore, the splenocytes from BMDC-dLN-immunized mice produced more interferon gamma, IL-4, IL-6, and IL-2, and they had a higher proliferation rate than other groups when re-stimulated with OVA. Hence, BMDC-dLN could be a promising DC-based scaffold for in vivo delivery to induce potent antitumor immunity.

AB - In recent decades, the decellularized extracellular matrix (ECM) has shown potential as a promising scaffold for tissue regeneration. In this study, an organic acid decellularized lymph node (dLN) was developed as a carrier for dendritic cells (DCs) to induce antitumor immunity. The dLNs were prepared by formic acid, acetic acid, or citric acid treatment. The results showed highly efficient removal of cell debris from the lymph node and great preservation of ECM architecture and biomolecules. In addition, bone marrow dendritic cells (BMDCs) grown preferably inside the dLN displayed the maturation markers CD80, CD86, and major histocompatibility complex (MHC)-II, and they produced high levels of interleukin (IL)-1β, IL-6, and IL-12 cytokines when stimulated with ovalbumin (OVA) and CpG oligodeoxynucleotides (CPG-ODN). In an animal model, the BMDC-dLN completely rejected the E.G7-OVA tumor. Furthermore, the splenocytes from BMDC-dLN-immunized mice produced more interferon gamma, IL-4, IL-6, and IL-2, and they had a higher proliferation rate than other groups when re-stimulated with OVA. Hence, BMDC-dLN could be a promising DC-based scaffold for in vivo delivery to induce potent antitumor immunity.

KW - Cancer immunotherapy

KW - Cell-based therapy

KW - Decellularized scaffold

KW - Dendritic cell

KW - Lymph node

UR - http://www.scopus.com/inward/record.url?scp=85074366561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074366561&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics11110553

DO - 10.3390/pharmaceutics11110553

M3 - Article

AN - SCOPUS:85074366561

VL - 11

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 11

M1 - 553

ER -